Email ID : 
Password : 
Forgot Your Password ? 

Only Report Titles
Titles & Keywords
NOTE: Site best viewed with Internet Explorer
  MOLECULAR DIAGNOSTICS
A Global Strategic Business Report

This report analyzes the worldwide markets for Molecular Diagnostics in Millions of US$. The specific product segments analyzed are Infectious Disease Testing, Pharmacogenomics, and Cancer Screening. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 101 companies including many key and niche players worldwide such as Abbott Laboratories, Abbott Molecular, Applera Corporation, Celera, Biomérieux, CytoCore Inc., GE Healthcare, Gen-Probe Inc., Genzyme Corporation, Genzyme Genetics, MiraiBio, Inc., Nanogen, Novartis Vaccines & Diagnostics, Inc., QIAGEN N. V, Digene Corporation, Quest Diagnostics Incorporated, Roche Diagnostics, Siemens Healthcare Diagnostics, and Tecan Group Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

CODE:    MCP-1226  PAGES:    531
PRICE:    $3950  DATE:       April 2008
COMPANIES:  101  MARKET DATA TABLES:   165
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

 TABLE OF CONTENTS  
  MOLECULAR DIAGNOSTICS (Complete Report) Pages : 531   | $3950
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS4$100
   Study Reliability and Reporting Limitations...I-1  
   Disclaimers...I-2
Data Interpretation & Reporting Level...I-2
  
   Quantitative Techniques & Analytics...I-3
Product Definitions and Scope of Study...I-3
Infectious Diseases Testing...I-3
  
   Pharmacogenomics...I-4
Cancer Screening...I-4
  
II. EXECUTIVE SUMMARY82$2250
  1. Industry Overview...II-13 $300  
   Global Market Outlook...II-1
Molecular Diagnostics – The Fastest Growing Medical Diagnostic Technology...II-1
New Applications Hold Promising Potential...II-1
1$100
   Automated Systems – Prime Target...II-2
Infectious Disease Testing Drives the Diagnostics Market...II-2
1$100
   The Future in Store...II-3
1$100
  2. A Review of Medical Diagnostics Market...II-46 $800  
   Clinical Diagnostics Industry – Trends and Tendencies...II-4 1$100
   Table 1: Worldwide In Vitro Diagnostics (IVD) Market (2005 & 2006)– Percentage Breakdown by Value Sales for Immunochemistry, Diabetes, Clinical Chemistry, Point-of-care testing, Molecular Diagnostics, Hematology, Coagulation, Urinalysis, and Others (includes corresponding Graph/Chart)...II-5

Table 2: Leading Players in the Worldwide In Vitro Diagnostics (IVD) Market (2005) – Percentage Breakdown by Value Sales for Roche Diagnostics, Abbott Laboratories, Johnson & Johnson, Bayer Diagnostics, Beckman Coulter, Dade Behring, and Others (includes corresponding Graph/Chart)...II-5
1$300
   Table 3: Leading Players in the Worldwide Molecular Diagnostics Market (2006) – Percentage Breakdown by Value Sales for Roche Diagnostics, Chiron, Bayer Diagnostics, GenProbe, Abbott Laboratories, Becton Dickinson, and Others (includes corresponding Graph/Chart)...II-6
Diagnostic Tests – Classification...II-6
1$300
   Table 4: Leading Players in the Worldwide Genetic Testing Market (2006) – Percentage Breakdown by Value Sales for Roche Diagnostics /Affymetrix, Abbott Laboratories, Bio-Rad Laboratories, and Others(includes corresponding Graph/Chart)...II-7
Nucleic Acid Diagnostics Market – An Overview...II-7
1$300
   Molecular Diagnostics – Growth Drivers...II-81$100
   Molecular Diagnostics – A Replacement and Enabling Technology...II-9
Molecular Diagnostics for Lymphoid Malignancies...II-9
1$100
  3. Competitive Dynamics in the Molecular Diagnostics Market...II-102 $200  
   Key Players and Their Technologies...II-10
The Top Tier...II-10
Mid-Sized and Small Companies...II-10
2$200
  4. Market Trends & Issues...II-127 $500  
   Market Consolidations on the Way to Integrate in Vivo and in Vitro
  Diagnostics...II-12
Global Molecular Diagnostics on High Growth Curve...II-12
Pharmaceutical Firms Carving Their Niche in Molecular Diagnostic Market...II-12
Towards Tailoring the Right Treatment for the Right Disease...II-12
1$100
   Disease-Specific Molecular Diagnostics to Deliver Improved Clinical Outcomes...II-13
Molecular Diagnostics and Intellectual Property...II-13
Business Opportunities in the Offing...II-13
1$100
   Challenges Facing the Molecular Diagnostic Market...II-14
Medical Training and Practice Challenges...II-14
Shortcomings to Overcome...II-14
1$100
   Limited Reimbursements by Third Party Payers – A Stumbling Block...II-15
Hurdles All the Way for Companies Eyeing Molecular Diagnostics...II-15
1$100
   Product Marketing – Key to Commercial Success...II-16
Integration of Molecular Diagnostics into Therapeutics...II-16
1$100
   Molecular Diagnostics – Moving from Centralization to Decentralization...II-17
Migrating to Decentralized Format...II-17
Going Ahead with Decentralization...II-17
2$200
  5. Product & Technology Overview...II-1911 $800  
   Molecular Diagnostics – Definition & Scope...II-19
Molecular Diagnostics – Impact on Healthcare...II-19
1$100
   Utility of Molecular Diagnostic Tests...II-20
Background of Molecular Diagnostics...II-20
Major Molecular Diagnostics Company Products...II-20
1$100
   Major Test Launches in Molecular Diagnostics...II-21
Unabated Developments in Molecular Diagnostics Technology...II-21
Signal Amplification Technologies...II-21
PCR – New Developments...II-21
1$100
   Major Applications of Real-Time PCR...II-22
Quantitative Real-Time PCR for Molecular Diagnostics...II-22
Signal Detection and Quantification...II-22
1$100
   Quantitative Real-Time RT-PCR Analysis...II-23
Applications of Quantitative Real-Time PCR Analysis...II-23
Non-PCR Methods...II-23
Other Signal Amplification Technologies...II-23
DNA Probe Based Products...II-23
1$100
   Direct Detection of Specific Nucleic Acid Sequences...II-24
Nucleic Acid Amplification and Detection...II-24
1$100
   DNA Sequencing and Gene Detection...II-25
Arrays of Immobilized Probes (DNA Chips) in Gene Detection...II-25
1$100
   RNA Diagnostics...II-26
Complementary Molecular Diagnostic Technologies...II-26
Fluorescent in situ hybridization (FISH)...II-26
DNA Biochips / Microarrays...II-26
1$100
   Biosensors...II-271$100
   Proteomic Technologies for Molecular Diagnostics...II-28
Nanotechnology for Molecular Diagnostics...II-28
1$100
   Technologies on the Anvil...II-29
Haplotype Analysis – A Distant Possibility...II-29
Chronic Multi-Gene Defects Now Diagnosable...II-29
1$100
  6. An Insight into Applications of Molecular Diagnostics...II-305 $600  
   Infectious Diseases Testing...II-30
Activity in the Field...II-30
1$100
   Identifying Multidrug Resistance...II-31
Infectious Disease Treatment Monitoring...II-31
Other Infectious Diseases Applications...II-31
Genetic Disease Testing Applications...II-31
1$100
   Pharmacogenomics – Prognosis Based on Genomics...II-32
Cancer Screening & Diagnosis...II-32
1$100
   Molecular Tests Lead the Way for Cancer IVD Market Growth...II-33 1$100
   Table 5: Worldwide Cancer Diagnostic Testing Market (2006): Percentage Breakdown of Value Sales for Immunoassays, Histology (IHC/ISH), Pap Testing, Flow Cytometry, Prostate-Specific Antigen, Molecular Assays, and Fecal Occult Blood Test (includes corresponding Graph/Chart)...II-34
Other Testing Applications...II-34
1$300
  7. Product Developments/Introductions...II-357 $500  
   TMD Launches Test for K-ras Mutations in Colorectal Cancer Patients...II-35
CombiMatrix Releases Updated Version of Constitutional Genetic Array Test...II-35
Myriad Introduces TheraGuide 5-FU...II-35
CMDX Unveils First HemeScan™ Prognostic...II-35
CombiMatrix Introduces HemeScan™ MDS...II-35
1$100
   Genzyme Rolls Out Two New Molecular Tests...II-36
Dade Behring Launches The Quadriga BeFree...II-36
BD Diagnostics Introduces The BD Viper System...II-36
Genzyme Introduces P53 Mutation Analysis...II-36
CombiMatrix Molecular Diagnostics Rolls Out A New Melanoma Test...II-36
Qiagen Launches Fast Cycling PCR Product Line...II-36
Genzyme Releases Molecular Assay for Colorectal Cancer Patients...II-36
1$100
   Roche Diagnostics Launches LightCycler 480 System...II-37
Roche Diagnostics Introduces AmpliChip CYP450 Test...II-37
SEQUENOM Unveils iPLEX™...II-37
SEQUENOM Develops a Novel Process...II-37
Cerner Corp Develops Cerner Millennium(R) PathNet Helix(TM)...II-37
Roche Diagnostics Launches Amplicor HPV Test...II-37
Gen-Probe Launches Procleix Ultrio Assay in Europe...II-37
1$100
   Gen-Probe Launches TIGRIS®DTS™ System...II-38
BD Biosciences Introduces BD QZyme™ Assay...II-38
Epoch Biosciences Releases MGB Eclipse™...II-38
QIAGEN Unveils BioRobot MDx DSP Device...II-38
Digene Unveils DNAwithPap...II-38
Exact Sciences Launches Non-Invasive Test for Colorectal Cancer...II-38
TDT Introduces GCC-B1 Blood Test to Detect Colorectal Cancer...II-38
1$100
   AcroMetrix Joins Hands with Nabi to Introduce ViroSure...II-39
Orchid Cellmark Introduces DNA Express Service...II-39
Roche Develops New IVD Real-Time PCR Instrument...II-39
Nanogen Rolls Out First Ever ASR...II-39
Digene Introduces Hybrid Capture...II-39
Digene’s Hybrid Capture 2 HPV DNA Test to Effectively Identify Cervical
  Cancer...II-39
1$100
   PGD to Eliminate Human Eggs Affected with Alzheimer's Disease...II-40
Esoterix Introduces New HCV Testing Program...II-40
Gen-Probe Releases New APTIMA Combo 2 Assay...II-40
Nycomed’s NeoSpect to Identify Suspected Lung Cancer...II-40
DNAPrint Introduces New Services to Assist Forensic Market...II-40
1$100
   IMBG Develops an Efficient Procedure to Treat Diseases...II-41
1$100
  8. Recent Industry Activity...II-4222 $1200  
   Vermillion, Johns Hopkins Ink Agreements to Develop Molecular Diagnostic Tests...II-42
Beckman Coulter Inks Licensing Agreements with National University of Ireland...II-42
Roche Takes over BioVeris...II-42
Siemens Acquires Dade Behring...II-42
DiagnoCure Acquires Catalyst Oncology...II-42
1$100
   Burrill & Co Takes over Expression Diagnostics...II-43
Solis Acquires Bertrand...II-43
ParagonDx LLC Purchases Gentris Diagnostics...II-43
Beckman Collaborates to Discover CVD Symptoms...II-43
Exiqon to Take over Oncotech...II-43
Roche to Acquire Ventana...II-43
1$100
   Qiagen Merges with Digene...II-44
Qiagen & Bio One Capital Collaborates...II-44
AGT & MAL Signs MoU...II-44
Qiagen Obtains Licenses to Real-Time PCR...II-44
Cepheid Purchases Sangtec...II-44
1$100
   Source MDx Collaborates with Pfizer...II-45
Nanosphere Receives FDA Clearance for Second Molecular Diagnostic Test...II-45
QIAGEN Acquires eGene...II-45
Quest Diagnostics Acquires AmeriPath...II-45
Mayo and ILMN Team up to Develop Molecular Diagnostics for Complex Diseases...II-45
CHEO and ILMN Team up to Develop Molecular Diagnostics for Newborn Screening...II-45
1$100
   Siemens Medical Solutions USA Sets Up Siemens Medical Solutions Diagnostics...II-46
Novartis Acquires Chiron...II-46
Quest Diagnostics Acquires Focus Diagnostics...II-46
Becton Dickinson Acquires GeneOhm...II-46
Iris International Acquires Leucadia Technologies...II-46
Predicant Biosciences Acquires Pathwork Informatics...II-46
AmeriPath Acquires Rose Pathology Associates...II-46
1$100
   Nanogen Acquires Amplimedical’s Diagnostics Division...II-47
Nanogen Acquires Immunoassay Test Business of Spectral Diagnostics...II-47
Fisher Scientific Acquires Athena...II-47
Qiagen Acquires Genaco...II-47
Bio-Rad Acquires Blackhawk BioSystems...II-47
IRIS International Acquires Leucadia Technologies...II-47
Qiagen Acquires Shenzhen PG Biotech...II-47
1$100
   Qiagen Acquires Artus GmbH...II-48
Nanogen and Fisher Increases Agreement Tenure...II-48
Qiagen Signs An Agreement with Gentra...II-48
Qiagen Inks an Agreement with VLA...II-48
Stratagene Signs an Agreement with AROS...II-48
Bayer Inks an Agreement with Hamilton Company...II-48
1$100
   Prodesse and Invitrogen Sign a Pact...II-49
Illumina Forms Collaboration with ReaMetrix...II-49
PerkinElmer Signs an Agreement with Jacobi Medical...II-49
UniPath and Roche Diagnostics Sign an Accord...II-49
Qiagen Alliances with Eppendorf...II-49
Olympus and Cangen Extends their Research Collaboration...II-49
1$100
   Toppan, Shimadzu and Third Wave Collaborate to Develop A POC Molecular Diagnostic
  Instrument...II-50
Focus Diagnostics Signs an Agreement with Stratagene...II-50
Innogenetics Inks an Agreement with Roche Diagnostics...II-50
The University of Goettingen, Bruker Daltonik and PANATecs Collaborate to Develop New
  Molecular Diagnostic Assays for Rheumatoid Arthritis...II-50
Focus Diagnostics Enters into an Agreement with Luminex...II-50
1$100
   QIAGEN Expands Strategic Alliance with Protedyne...II-51
Specialty Laboratories Teams Up with SEQUENOM and Siemens...II-51
Gen-Probe Enters into a Licensing Agreement with Corixa...II-51
Gen-Probe Inks a Supply and Purchase Agreement with F. Hoffmann-La Roche...II-51
Gen-Probe Enters into a Licensing Agreement with AdnaGen...II-51
1$100
   Roche Establishes New Polymerase Chain Reaction (PCR) Manufacturing Center...II-52
Ambion Establishes a Subsidiary in Japan...II-52
Gen-Probe Gains FDA Approval for APTIMA®...II-52
Blood Center of Southeastern Wisconsin Adopts Ambion’s Signature™ CF 2.0 ASR...II-52
Orchid Biosciences, Inc. Becomes Orchid Cellmark Inc...II-52
Roche Acquires IGEN International...II-52
GE Takes Over Amersham Plc...II-52
1$100
   Nanogen Acquires SYN•X PHARMA...II-53
Nanogen Merges with Epoch Biosciences...II-53
Sequenom Enters into Collaboration with Siemens...II-53
TMD Joins Hands with University of Texas...II-53
GE Global and Two other Companies Enters into a Joint Research Collaboration...II-53
Third Wave and BML Extend Partnership to Promote Molecular Diagnostic Tests...II-53
ViroLogic Signs an Agreement with ACLARA...II-53
1$100
   Abbott and BioGenex Sign an Agreement...II-54
Novation Signs a Pact with Bayer Diagnostics...II-54
Osmetech Enters into a Licensing Agreement with LGC Limited...II-54
Licensing Agreement between DxS Ltd and Sangtec Molecular Diagnostics...II-54
EraGen Biosciences Strikes a Deal with Inter Medico...II-54
Nanogen Bags Patent for Molecular Diagnostics and Optical Waveguides Systems...II-54
1$100
   Gen-Probe Secures Regulatory Approval for PROCLEIX ® ULTRIO™ Assay...II-55
Gen-Probe Bags FDA Approval to Use TIGRIS DTS System for STD Testing...II-55
Gen-Probe Acquires Majority Stake in MLT...II-55
AmeriPath in Strategic Alliance with Roche...II-55
Abbott and Promega to Offer Nucleic Acid Extraction Products...II-55
Ambion RNA to Offer Services Through BBI...II-55
1$100
   STMicroelectronics Inks an Agreement with Mobidiag...II-56
BBI Contracts with IDS...II-56
Focus to Assist FDA in Evaluation of Antimicrobial Resistance...II-56
Bayer Acquires Rights to Detect HCV and HIV Antibodies...II-56
Cenetron in Strategic Alliance with Roche...II-56
Saint Luke's Health System in Alliance with Roche...II-56
1$100
   US LABS Adds Gene Expression Profiling Capabilities on (FFPE) Tissue...II-57
Bayer Acquires Visible Genetics...II-57
Qiagen Enters into an Agreement with RMS...II-57
Dabur Starts a New Molecular Diagnostic Lab...II-57
Roche Gains Rights for Cervical-Cancer Testing Market...II-57
1$100
   Ventana Acquires License From MDI...II-58
Genzyme Genetics Gains Rights for Genzyme Molecular’s Cancer Diagnostics...II-58
Abbott in Strategic Alliance with Celera...II-58
MDI and DiagnoCure Join Hands to Integrate ImmunoCyt/uCyt with InPath...II-58
MDI and PMI to Jointly Promote Lung Cancer Detection System...II-58
1$100
   MDI in Agreement with Esoterix...II-59
MDI to Expand Product Base in China...II-59
Abbott and Tecan to Offer Devices for Molecular Diagnostic Assays...II-59
Invirion Extends Licensing Agreement with MDI...II-59
Ambion RNA Grants License to Celera...II-59
Morewood and IT&M to Introduce New Micro Array System...II-59
1$100
   Ambion RNA Constructs New Manufacturing Facility...II-60
LabCorp Teams up with Celera...II-60
Athena Launches New DNA Testing for TSC...II-60
Genezyme Genetics Expands Cancer Testing Services...II-60
Promega Teams Up with Abbott...II-60
ChromaVision and Ventana Join Hands to Market Testing Process that Identifies
  HPV...II-60
1$100
   OraSure in Agreement with Abbott...II-61
Nanogen and Bionomics to Jointly Develop IVD for Epilepsy...II-61
DiagnoCure and Compugen Join Hands to Develop Tests to Identify Epithelial
  Cancers...II-61
OraSure Gets FDA Approval for OraQuick Rapid HIV-1 Test...II-61
Ampersand and Accumed Merged to Form MDI...II-61
Abbott Acquires Vysis...II-61
1$100
   Millennium and Abbott Forge 5-Year Drug Deal...II-62
Bode Enters into Agreement to Undertake DNA Testing...II-62
BD Contracts with TriPath to Develop Molecular Diagnostics...II-62
TriPath Installs New Interactive System...II-62
Archemix in Strategic Alliance with RPI...II-62
1$100
   AmeriPath Strengthens Relationship with Genomics Collaborative...II-63
Cepheid and Infectio Join Hands to Form Aridia...II-63
Myriad Enters into Agreement with NCI...II-63
Nanogen Gains Further Rights for Electronic Microarray Technology...II-63
1$100
  9. Focus on Select Global Players...II-647 $500  
   Abbott Laboratories (US)...II-64
Abbott Molecular...II-64
Applera Corporation (US)...II-64
Celera (US)...II-64
1$100
   Biomérieux (France)...II-65
CytoCore Inc (US)...II-65
1$100
   GE Healthcare (US)...II-66
Gen-Probe Inc (US)...II-66
Genzyme Corporation (US)...II-66
1$100
   Genzyme Genetics (US)...II-67
MiraiBio, Inc. (US)...II-67
Nanogen (US)...II-67
Novartis Vaccines & Diagnostics, Inc. (US)...II-67
1$100
   QIAGEN N. V (The Netherlands)...II-68
Digene Corporation (USA)...II-68
1$100
   Quest Diagnostics Inc. (US)...II-69
Roche Diagnostics (Switzerland)...II-69
Siemens Healthcare Diagnostics (US)...II-69
1$100
   Tecan Group Ltd. (Switzerland)...II-70
1$100
  10. Global Market Perspective...II-71   
   Table 6: World Recent Past, Current & Future Market Analysis for Molecular Diagnostics by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)...II-711$300
   Table 7: World Long-term Projections for Molecular Diagnostics by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...II-721$300
   Table 8: World 10-Year Perspective for Molecular Diagnostics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2003, 2008 & 2012(includes corresponding Graph/Chart)...II-731$300
   Table 9: World Recent Past, Current & Future Market Analysis for Molecular Diagnostics (Infectious Disease Testing) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)...II-741$300
   Table 10: World Long-term Projections for Molecular Diagnostics (Infectious Disease Testing) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...II-751$300
   Table 11: World 10-Year Perspective for Molecular Diagnostics (Infectious Disease Testing) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)...II-761$300
   Table 12: World Recent Past, Current & Future Market Analysis for Molecular Diagnostics (Pharmacogenomics) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)...II-771$300
   Table 13: World Long-term Projections for Molecular Diagnostics (Pharmacogenomics) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...II-781$300
   Table 14: World 10-Year Perspective for Molecular Diagnostics (Pharmacogenomics) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)...II-791$300
   Table 15: World Recent Past, Current & Future Market Analysis for Molecular Diagnostics (Cancer Screening) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)...II-801$300
   Table 16: World Long-term Projections for Molecular Diagnostics (Cancer Screening) by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...II-811$300
   Table 17: World 10-Year Perspective for Molecular Diagnostics (Cancer Screening) by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)...II-821$300
III. MARKET64$1950
  1. United States...III-130 $1225  
   A. Market Analysis...III-1
A Precursor to the Molecular Diagnostics Market in the US...III-1
Molecular Diagnostics Heavily Tied to Proteomics and Genomics...III-1
Burgeoning Potential for Genetic Testing...III-1
1$75
   Regulatory Environment...III-2
Regulations Out for Molecular Diagnostic Testing of HPV...III-2
1$75
   Limited Reimbursements - A Major Hindrance...III-3
Key Players...III-3
4$300
   Product Launches...III-75$375
   Strategic Developments...III-1217$775
   B. Market Analytics...III-29
Table 18: US Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment – Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)...III-29

Table 19: US Long-term Projections for Molecular Diagnostics by Product Segment – Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-29
1$150
   Table 20: US 10-Year Perspective for Molecular Diagnostics by Product Segment – Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, andCancer Screening Markets for 2003, 2008 & 2012(includes corresponding Graph/Chart)...III-30
1$150
  2. Canada...III-313 $275  
   A. Market Analysis...III-31
Strategic Developments...III-31
1$75
   B. Market Analytics...III-32
Table 21: Canadian Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment – Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)...III-32

Table 22: Canadian Long-term Projections for Molecular Diagnostics by Product Segment – Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart...III-32
1$150
   Table 23: Canadian 10-Year Perspective for Molecular Diagnostics by Product Segment – Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-33
1$150
  3. Japan...III-343 $275  
   A. Market Analysis...III-34
Strategic Developments...III-34
1$75
   B. Market Analytics...III-35
Table 24: Japanese Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment – Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)...III-35

Table 25: Japanese Long-term Projections for Molecular Diagnostics by Product Segment – Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-35
1$150
   Table 26: Japanese 10-Year Perspective for Molecular Diagnostics by Product Segment – Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-36
1$150
  4. Europe...III-376 $650  
   A. Market Analysis...III-37
Insight into Molecular Diagnostics Markets in Europe...III-37
1$75
   Table 27: European Molecular Diagnostics Market (2006) – Market Shares of Leading Players by Value Sales for Roche Diagnostics, Abbott Diagnostics, Bayer Diagnostics, Becton Dickinson, Digene Diagnostics, BioMerieux and Others (includes corresponding Graph/Chart)...III-38
Product Launches...III-38
1$150
   B. Market Analytics...III-39
Table 28: European Recent Past, Current & Future Analysis for Molecular Diagnostics by Geographic Region – France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)...III-39
1$150
   Table 29: European Long-term Projections for Molecular Diagnostics by Geographic Region – France, Germany, Italy, UK, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-40

Table 30: European Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment – Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)...III-40
1$150
   Table 31: European Long-term Projections for Molecular(includes corresponding Graph/Chart) Diagnostics by Product Segment –Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-41

Table 32: European 10-Year Perspective for Molecular Diagnostics by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, and Rest of Europe Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-41
1$150
   Table 33: European 10-Year Perspective for Molecular Diagnostics by Product Segment – Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-42
1$150
  4a. France...III-433 $250  
   A. Market Analysis...III-43
bioMérieux – A Key French Player...III-43
Strategic Development...III-43
1$75
   B. Market Analytics...III-44
Table 34: French Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment – Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)...III-44

Table 35: French Long-term Projections for Molecular Diagnostics by Product Segment – Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-44
1$150
   Table 36: French 10-Year Perspective for Molecular Diagnostics by Product Segment – Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-45
1$150
  4b. Germany...III-462 $225  
   Market Analysis...III-46
Table 37: German Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment – Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)...III-46
1$150
   Table 38: German Long-term Projections for Molecular Diagnostics by Product Segment – Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-47

Table 39: German 10-Year Perspective for Molecular Diagnostics by Product Segment – Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-47
1$150
  4c. Italy...III-482 $225  
   Market Analysis...III-48
Table 40: Italian Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment – Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)...III-48
1$150
   Table 41: Italian Long-term Projections for Molecular Diagnostics by Product Segment – Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-49

Table 42: Italian 10-Year Perspective for Molecular Diagnostics by Product Segment – Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-49
1$150
  4d. United Kingdom...III-503 $250  
   A. Market Analysis...III-50
Product Launch...III-50
Strategic Development...III-50
1$75
   B. Market Analytics...III-51
Table 43: UK Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment – Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)...III-51

Table 44: UK Long-term Projections for Molecular Diagnostics by Product Segment – Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-51
1$150
   Table 45: UK 10-Year Perspective for Molecular Diagnostics by Product Segment – Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-52
1$150
  4e. Rest of Europe...III-537 $475  
   A. Market Analysis...III-53
Key Players...III-53
1$75
   Product Launches...III-541$75
   Strategic Developments...III-553$225
   B. Market Analytics...III-58
Table 46: Rest of Europe Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment – Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)...III-58

Table 47: Rest of Europe Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment – Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-58
1$150
   Table 48: Rest of Europe 10-Year Perspective for Molecular Diagnostics by Product Segment – Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-59
1$150
  5. Asia-Pacific...III-603 $250  
   A. Market Analysis...III-60
Indian Diagnostic Market...III-60
Strategic Developments...III-60
1$75
   B. Market Analytics...III-61
Table 49: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment – Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)...III-61
1$150
   Table 50: Asia-Pacific Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment – Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-62

Table 51: Asia-Pacific 10-Year Perspective for Molecular Diagnostics by Product Segment – Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-62
1$150
  6. Rest of World...III-632 $300  
   Market Analysis...III-63
Table 52: Rest of World Recent Past, Current & Future Analysis for Molecular Diagnostics by Product Segment – Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)...III-63
1$150
   Table 53: Rest of World Long-term Projections for Molecular Diagnostics by Product Segment – Infectious Disease Testing, Pharmacogenomics and Cancer Screening Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)...III-64

Table 54: Rest of World 10-Year Perspective for Molecular Diagnostics by Product Segment – Percentage Breakdown of Dollar Sales for Infectious Disease Testing, Pharmacogenomics, and Cancer Screening Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)...III-64
1$150
IV. COMPETITIVE LANDSCAPE 369$995
  
Total Companies Profiled: 100 (including Divisions/Subsidiaries - 120 )

Region/Country                 Players


The United States                 87   
Canada                             5
Europe                            26
     France                        3
     Germany                       6
     The United Kingdom            5
     Rest of Europe               12
Asia-Pacific (Excluding Japan)     2
Click here to request a full table of contents and more details on this project.		  
 
 
Due to the proprietary nature, our previews are offered only to manufacturers, top-tier management consultants, investment banks, and investment research groups.

© Copyrights 2009, Global Industry Analysts, Inc., USA.